Fig. 4

Integrin ανβ5 blockade in vitro decreases TGF-β1 release and protein production of typical MyoFB markers. a Secreted amount of active TGF-β1 in conditioned media of WKY- and SHR-CF after treatments with 0.5 μM cilengitide. ELISA data are expressed as mean ± SD, n = 5/group. The experiments on cell surnatants were performed in triplicate. Protein expression of integrin ανβ5 (b) and collagen I (c) in WKY- and SHR-CF after treatments with 5 ng/ml TGF-β1, TGF-β1 + 0.5 μM cilengitide, or cilengitide. d Representative images of immunofluorescence performed for α-SMA on WKY- and SHR-CF. Scale bar = 100 μm. e Protein expression of α-SMA in WKY- and SHR-CF after treatments with 5 ng/ml TGF-β1, TGF-β1 + 0.5 μM cilengitide, or cilengitide. All Western blot quantification data are expressed as mean ± SD after β-tubulin normalization. The experiments on cells were performed in triplicate, with a n = 5/group. 2-way ANOVA with Bonferroni’s post-test: *p < 0.05, **p < 0.01, ***p < 0.001